Latest Breaking News On - தழுவி மயோ மதிப்பெண் - Page 1 : comparemela.com

Upadacitinib Meets Endpoints in Ulcerative Colitis Maintenance Trial The upadacitinib ulcerative colitis program includes 3 pivotal studies that have enrolled more than 1300 patients with moderately to severely active ulcerative colitis. (Credit: Getty Images.) A phase 3 study evaluating upadacitinib for the maintenance treatment of adults with moderately to severely active ulcerative colitis met its primary and all secondary endpoints. The multicenter, randomized, double-blind, placebo-controlled maintenance study (ClinicalTrials.gov Identifier: NCT02819635) evaluated upadacitinib in 451 adults with moderately to severely active ulcerative colitis. Following an 8-week induction treatment period of upadacitinib 45mg once daily, 746 patients who achieved clinical response were randomly assigned to receive upadacitinib 15mg (n=148), 30mg (n=154), or placebo (n=149) for an additional 52 weeks. 

Adapted mayo scoreதழுவி மயோ மதிப்பெண்